Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HIV Preventive Vaccine”

157 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 157 results

Early research (Phase 1)Study completedNCT00043511
What this trial is testing

Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 30
Early research (Phase 1)Study completedNCT00000774
What this trial is testing

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

Who this might be right for
HIV InfectionsHIV Seronegativity
National Institute of Allergy and Infectious Diseases (NIAID) 156
Early research (Phase 1)Study completedNCT00001053
What this trial is testing

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 36
Early research (Phase 1)Study completedNCT00000795
What this trial is testing

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 28
Early research (Phase 1)Study completedNCT00000972
What this trial is testing

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Who this might be right for
HIV InfectionsHIV Seronegativity
National Institute of Allergy and Infectious Diseases (NIAID) 64
Early research (Phase 1)Study completedNCT00069030
What this trial is testing

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 70
Early research (Phase 1)Study completedNCT00574600
What this trial is testing

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 48
Early research (Phase 1)Study completedNCT00000884
What this trial is testing

Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 84
Early research (Phase 1)Study completedNCT00000745
What this trial is testing

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 72
Early research (Phase 1)Study completedNCT00955006
What this trial is testing

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 17
Early research (Phase 1)Study completedNCT00000846
What this trial is testing

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 36
Early research (Phase 1)Study completedNCT00083603
What this trial is testing

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 150
Early research (Phase 1)Study completedNCT00124007
What this trial is testing

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 114
Early research (Phase 1)Study completedNCT00111605
What this trial is testing

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 144
Early research (Phase 1)UnknownNCT00062530
What this trial is testing

Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 38
Early research (Phase 1)Study completedNCT00000777
What this trial is testing

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

Who this might be right for
HIV InfectionsPregnancyHIV Seronegativity
National Institute of Allergy and Infectious Diseases (NIAID) 24
Early research (Phase 1)Study completedNCT00027261
What this trial is testing

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

Who this might be right for
HIV InfectionsHIV Seronegativity
National Institute of Allergy and Infectious Diseases (NIAID) 110
Early research (Phase 1)Study completedNCT00001052
What this trial is testing

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 110
Early research (Phase 1)Study completedNCT00709605
What this trial is testing

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 31
Early research (Phase 1)Study completedNCT00000957
What this trial is testing

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 30
Next Page